Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions
- 1 November 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 2 (11), 931-941
- https://doi.org/10.1158/1940-6207.capr-09-0121
Abstract
Epidemiologic and preclinical data support the oral cancer prevention potential of green tea extract (GTE). We randomly assigned patients with high-risk oral premalignant lesions (OPL) to receive GTE at 500, 750, or 1,000 mg/m2 or placebo thrice daily for 12 weeks, evaluating biomarkers in baseline and 12-week biopsies. The OPL clinical response rate was higher in all GTE arms (n = 28; 50%) versus placebo (n = 11; 18.2%; P = 0.09) but did not reach statistical significance. However, the two higher-dose GTE arms [58.8% (750 and 1,000 mg/m2), 36.4% (500 mg/m2), and 18.2% (placebo); P = 0.03] had higher responses, suggesting a dose-response effect. GTE treatment also improved histology (21.4% versus 9.1%; P = 0.65), although not statistically significant. GTE was well tolerated, although higher doses increased insomnia/nervousness but produced no grade 4 toxicity. Higher mean baseline stromal vascular endothelial growth factor (VEGF) correlated with a clinical (P = 0.04) but not histologic response. Baseline scores of other biomarkers (epithelial VEGF, p53, Ki-67, cyclin D1, and p16 promoter methylation) were not associated with a response or survival. Baseline p16 promoter methylation (n = 5) was associated with a shorter cancer-free survival. Stromal VEGF and cyclin D1 expression were downregulated in clinically responsive GTE patients and upregulated in nonresponsive patients at 12 weeks (versus at baseline). An extended (median, 27.5 months) follow-up showed a median time to oral cancer of 46.4 months. GTE may suppress OPLs, in part through reducing angiogenic stimulus (stromal VEGF). Higher doses of GTE may improve short-term (12-week) OPL outcome. The present results support longer-term clinical testing of GTE for oral cancer prevention.Other Versions
This publication has 55 references indexed in Scilit:
- Perspectives for Cancer Prevention With Natural CompoundsJournal of Clinical Oncology, 2009
- Epigallocatechin 3-Gallate and Green Tea Catechins: United They Work, Divided They FailCancer Prevention Research, 2009
- Foodstuffs for Preventing Cancer: The Preclinical and Clinical Development of BerriesCancer Prevention Research, 2009
- Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral PremalignancyJournal of Clinical Oncology, 2009
- p16 Promoter Methylation Is a Potential Predictor of Malignant Transformation in Oral Epithelial DysplasiaCancer Epidemiology, Biomarkers & Prevention, 2008
- Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung AdenocarcinomasCancer Prevention Research, 2008
- Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitorInternational Journal of Cancer, 2008
- A Genotype-Phenotype Examination of Cyclin D1 on Risk and Outcome of Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 2008
- Tea and cancer prevention: Molecular mechanisms and human relevanceToxicology and Applied Pharmacology, 2007
- Cell Cycle Dysregulation by Green Tea Polyphenol Epigallocatechin-3-GallateBiochemical and Biophysical Research Communications, 2000